Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699121 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
A Phase 2 study of Primary Sclerosing Cholangitis (PSC), sponsored by LISCure Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 7
- Study locations
NCT06699121: Recruiting Phase 2 study of Primary Sclerosing Cholangitis (PSC), sponsored by LISCure Biosciences.
NCT06699121 is a Phase 2 study of Primary Sclerosing Cholangitis (PSC) that is actively recruiting participants, run by LISCure Biosciences. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699121, a Phase 2 study of Primary Sclerosing Cholangitis (PSC), is actively recruiting participants, sponsored by LISCure Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
Primary Outcome
Occurrence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) by CTCAE V5.0
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LB-P8 low-dose
- DRUG LB-P8 high-dose
Study Locations (7)
California
- University of California Davis - Sacramento
Colorado
- UCHealth University of Colorado Hospital - Aurora
Iowa
- University Of Iowa Hospitals And Clinics - Iowa City
Maryland
- Mercy Medical Center - Baltimore
Minnesota
- Mayo Clinic - Rochester
Tennessee
- The Vanderbilt Clinic - Nashville
Washington
- Liver institute Northwest - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2025-11 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
What NCT06699121 shows while recruiting
NCT06699121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Primary Sclerosing Cholangitis (PSC) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06699121 lists 7 locations in 7 states (California, Colorado, Iowa).
Frequently Asked Questions
What is clinical trial NCT06699121 about?
NCT06699121 is a clinical study titled "A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC". The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
What is the current status of trial NCT06699121?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2025-11. Estimated completion is 2029-02.
What conditions does trial NCT06699121 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis (PSC).
What interventions are being tested in trial NCT06699121?
The interventions under investigation include: Placebo (DRUG), LB-P8 low-dose (DRUG), LB-P8 high-dose (DRUG).
Who is sponsoring clinical trial NCT06699121?
This trial is sponsored by LISCure Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699121 being conducted?
This trial has 7 study locations across California, Colorado, Iowa, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis (PSC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06699121's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia